320 lines
55 KiB
Text
320 lines
55 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK501095">
|
|
<meta name="ncbi_domain" content="lactmed">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK501095/?report=reader">
|
|
<meta name="ncbi_pagename" content="Risperidone - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Risperidone - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/lactmed/LM721/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/lactmed/ritlecitinib/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/lactmed/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="Drugs and Lactation Database (LactMed®) [Internet]">
|
|
<meta name="citation_title" content="Risperidone">
|
|
<meta name="citation_publisher" content="National Institute of Child Health and Human Development">
|
|
<meta name="citation_date" content="2025/01/15">
|
|
<meta name="citation_pmid" content="30000154">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK501095/">
|
|
<meta name="citation_keywords" content="risperidone">
|
|
<meta name="citation_keywords" content="Risperdal">
|
|
<meta name="citation_keywords" content="Rispolept">
|
|
<meta name="citation_keywords" content="Risperin">
|
|
<meta name="citation_keywords" content="Rispolin">
|
|
<meta name="citation_keywords" content="Sequinan">
|
|
<meta name="citation_keywords" content="Risperdal Consta">
|
|
<meta name="citation_keywords" content="Risperidonum">
|
|
<meta name="citation_keywords" content="Risperidona">
|
|
<meta name="citation_keywords" content="Uzedy">
|
|
<meta name="citation_keywords" content="Apexidone">
|
|
<meta name="citation_keywords" content="Psychodal">
|
|
<meta name="citation_keywords" content="Spiron">
|
|
<meta name="citation_keywords" content="Zophrenal">
|
|
<meta name="citation_keywords" content="UNII-L6UH7ZF8HC">
|
|
<meta name="citation_keywords" content="L6UH7ZF8HC">
|
|
<meta name="citation_keywords" content="HSDB 7580">
|
|
<meta name="citation_keywords" content="BRN 4891881">
|
|
<meta name="citation_keywords" content="R 64 766">
|
|
<meta name="citation_keywords" content="R 64766">
|
|
<meta name="citation_keywords" content="R 64,766">
|
|
<meta name="citation_keywords" content="3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Risperidone">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute of Child Health and Human Development">
|
|
<meta name="DC.Date" content="2025/01/15">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK501095/">
|
|
<meta name="description" content="Limited information indicates that maternal risperidone doses of up to 6 mg daily produce low levels in milk. Sedation, failure to thrive, jitteriness, tremors, abnormal muscle movements and respiratory depression have been reported in infants exposed to risperidone in milk. Because there is little published experience with risperidone during breastfeeding and little long-term follow-up data, other agents may be preferred, especially while nursing a newborn or preterm infant. Systematic reviews of second-generation antipsychotics concluded that risperidone seemed to be a second-line agent during breastfeeding because of the limited data available and higher excretion into milk relative to other agents.[1-3] A safety scoring system finds risperidone to be possible to use cautiously during breastfeeding.[4] Monitor the infant for drowsiness, weight gain, tremors, respiratory rate, abnormal muscle movements, and developmental milestones, especially if other antipsychotics are used concurrently.">
|
|
<meta name="og:title" content="Risperidone">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Limited information indicates that maternal risperidone doses of up to 6 mg daily produce low levels in milk. Sedation, failure to thrive, jitteriness, tremors, abnormal muscle movements and respiratory depression have been reported in infants exposed to risperidone in milk. Because there is little published experience with risperidone during breastfeeding and little long-term follow-up data, other agents may be preferred, especially while nursing a newborn or preterm infant. Systematic reviews of second-generation antipsychotics concluded that risperidone seemed to be a second-line agent during breastfeeding because of the limited data available and higher excretion into milk relative to other agents.[1-3] A safety scoring system finds risperidone to be possible to use cautiously during breastfeeding.[4] Monitor the infant for drowsiness, weight gain, tremors, respiratory rate, abnormal muscle movements, and developmental milestones, especially if other antipsychotics are used concurrently.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK501095/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-lactmed-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/lactmed/LM240/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK501095/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8B7F6C7D83A2010000000000150013.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK501095/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/lactmed/LM721/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Risperidone</div><div class="j">Drugs and Lactation Database (LactMed®) [Internet]</div></div><div class="tail"><a href="/books/n/lactmed/ritlecitinib/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK501095/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK501095/&text=Risperidone"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/lactmed/?report=reader">Title Information</a><a href="/books/n/lactmed/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK501095/?report=classic">Switch to classic view</a><a href="/books/NBK501095/pdf/Bookshelf_NBK501095.pdf">PDF (141K)</a><a href="/books/NBK501095/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK501095%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8B7F6C7D83A2010000000000150013.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK501095_"><span class="title" itemprop="name">Risperidone</span></h1><p class="fm-aai"><a href="#_NBK501095_pubdet_">Publication Details</a></p><p><em>Estimated reading time: 10 minutes</em></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><p>CASRN: 106266-06-2</p><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135018248" title="View this structure in PubChem" class="img_link" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&sid=135018248" alt="image 135018248 in the ncbi pubchem database" /></a><div id="LM240.Drug_Levels_and_Effects"><h2 id="_LM240_Drug_Levels_and_Effects_">Drug Levels and Effects</h2><div id="LM240.Summary_of_Use_during_Lactation"><h3>Summary of Use during Lactation</h3><p>Limited information indicates that maternal risperidone doses of up to 6 mg daily produce low levels in milk. Sedation, failure to thrive, jitteriness, tremors, abnormal muscle movements and respiratory depression have been reported in infants exposed to risperidone in milk. Because there is little published experience with risperidone during breastfeeding and little long-term follow-up data, other agents may be preferred, especially while nursing a newborn or preterm infant. Systematic reviews of second-generation antipsychotics concluded that risperidone seemed to be a second-line agent during breastfeeding because of the limited data available and higher excretion into milk relative to other agents.[<a class="bibr" href="#LM240.REF.1" rid="LM240.REF.1">1</a>-<a class="bibr" href="#LM240.REF.3" rid="LM240.REF.3">3</a>] A safety scoring system finds risperidone to be possible to use cautiously during breastfeeding.[<a class="bibr" href="#LM240.REF.4" rid="LM240.REF.4">4</a>] Monitor the infant for drowsiness, weight gain, tremors, respiratory rate, abnormal muscle movements, and developmental milestones, especially if other antipsychotics are used concurrently.</p></div><div id="LM240.Drug_Levels"><h3>Drug Levels</h3><p><i>Maternal Levels.</i> One mother taking risperidone 6 mg daily had milk and serum levels of risperidone and its active metabolite, 9-hydroxyrisperidone, measured over 24 hours. Results indicated that an exclusively breastfed infant would receive 0.84% of the maternal weight-adjusted dosage of risperidone and another 3.46% as 9-hydroxyrisperidone for a total of 4.3% of the maternal weight-adjusted dosage.[<a class="bibr" href="#LM240.REF.5" rid="LM240.REF.5">5</a>]</p><p>Two breastfeeding women taking 2 mg twice daily and 1.5 mg daily in 2 divided doses, respectively, and another with risperidone-induced galactorrhea taking 3 mg once daily were studied. Both risperidone and 9-hydroxyrisperidone were measured in milk. Milk levels of the drugs were rather flat during the 12 to 24 hours after the dose. The mean dose that an exclusively breastfed infant would receive was calculated to be 3.3% (range 2.2 to 4.7%) of the maternal weight-adjusted dosage.[<a class="bibr" href="#LM240.REF.6" rid="LM240.REF.6">6</a>]</p><p>A woman who was 1 week postpartum was started on oral risperidone 2 mg daily and increased to 3 mg once daily. On day 6 of therapy (dosage 2 mg daily) average milk levels at 3 hours after a dose were risperidone 2.5 mcg/L and 9-hydroxyrisperidone 10 mcg/L. On day 10 (dosage 2 mg daily) at 15 hours after a dose 9-hydroxyrisperidone averaged 1.2 mcg/L and risperidone was undetectable. On day 20 of therapy (dosage 3 mg daily) average milk levels at 16 hours after a dose were risperidone 0.1 mcg/L and 9-hydroxyrisperidone 2.5 mcg/L.[<a class="bibr" href="#LM240.REF.7" rid="LM240.REF.7">7</a>]</p><p>A woman took risperidone during pregnancy and breastfeeding. At 3 months postpartum, she provided 6 foremilk samples over a 24-hour period after her daily dose while she was taking a dose of 1 mg daily. Milk was analyzed for risperidone and 9-hydroxyrisperidone by HPLC. Risperidone could not be detected in milk (assay limit not specified). Breastmilk 9-hydroxyrisperidone was about 3 mcg/L at 1 and 24 hours later; its concentration was about 4 mcg/L at 2, 4, 8, 18 and 23 hours after the dose. The authors estimated that a fully breastfed infant would receive 4.7% of the maternal weight-adjusted dosage as 9-hydroxyrisperidone.[<a class="bibr" href="#LM240.REF.8" rid="LM240.REF.8">8</a>]</p><p>A woman with schizophrenia received brexpiprazole 2 mg once daily, risperidone 2 mg twice daily and quetiapine 12.5 mg twice daily during pregnancy and postpartum. The concentrations of risperidone and its active metabolite paliperidone in milk ranged from 0.40 to 0.93 mcg/L, and 3.2 to 4.1 mcg/L on day 4 approximately 2 hours after the last dose, on day 5 at 6.5 hours after the last dose, and on day 6 at 22 hours after the last dose.[<a class="bibr" href="#LM240.REF.9" rid="LM240.REF.9">9</a>]</p><p><i>Infant Levels.</i> In 2 breastfed infants (6 weeks and 3.3 months old) whose mothers were taking 2 mg twice daily and 1.5 mg daily in 2 divided doses, respectively, risperidone and 9-hydroxyrisperidone were both undetectable (<1 mcg/L) in the serums of the infants.[<a class="bibr" href="#LM240.REF.6" rid="LM240.REF.6">6</a>]</p><p>An infant was breastfed 6 times daily during maternal therapy with risperidone 2 mg once daily. Fifteen hours after the mother's last dose, the infant's plasma levels of risperidone was undetectable and 9-hydroxyrisperidone was 0.1 mcg/L.[<a class="bibr" href="#LM240.REF.7" rid="LM240.REF.7">7</a>]</p><p>An infant was exclusively breastfed on demand during maternal therapy with risperidone 1 mg daily. At 3 months of age, risperidone was undetectable in the infant's serum 6 hours after a maternal dose.[<a class="bibr" href="#LM240.REF.8" rid="LM240.REF.8">8</a>]</p><p>A breastfed newborn infant whose mother was taking brexpiprazole 2 mg once daily, risperidone 2 mg twice daily and quetiapine 12.5 mg twice daily during pregnancy and postpartum had serum levels measured. At birth, the cord blood level of risperidone was 2.5 mcg/L from maternal use during pregnancy. The neonate ingested small volumes of colostrum and milk 12 times from 46 to 86.5 hours after birth. Milk concentration of risperidone remained relatively constant between 2.5 and 2.9 mcg/L up to 137 hours postpartum when sampling was discontinued. At birth, the cord blood level of paliperidone was 4.1 mcg/L and it fell to 0.68 mcg/L at 137 hours postpartum.[<a class="bibr" href="#LM240.REF.9" rid="LM240.REF.9">9</a>]</p></div><div id="LM240.Effects_in_Breastfed_Infants"><h3>Effects in Breastfed Infants</h3><p>One woman took risperidone 4 mg daily during breastfeeding. Her infant showed no developmental abnormalities on examinations up to 9 months of age. Another mother took risperidone 6 mg daily during breastfeeding. Her infant showed no developmental abnormalities on examinations up to 12 months of age.[<a class="bibr" href="#LM240.REF.10" rid="LM240.REF.10">10</a>]</p><p>Two women taking risperidone 4 mg and 1.5 mg daily breastfed their infants of 3.3 months and 6 weeks of age, respectively, were achieving normal developmental milestones and had no adverse effects reported.[<a class="bibr" href="#LM240.REF.6" rid="LM240.REF.6">6</a>]</p><p>A 1 week postpartum woman was started on risperidone 2 mg daily and increased after 10 days to a dosage of 3 mg daily. She breastfed her infant 6 times daily. The infant was observed for 5 weeks of inpatient therapy and judged normal by a pediatric neurologist. No sedation or other adverse effects were observed in the infant. After 3 months of treatment with risperidone, the mother and infant were judged to be well.[<a class="bibr" href="#LM240.REF.7" rid="LM240.REF.7">7</a>]</p><p>An infant had been exclusively breastfed for 3 months during maternal therapy with risperidone 1 mg daily. A pediatric examination found the infant to have no neurological or physical abnormalities, and appeared to interact appropriately.[<a class="bibr" href="#LM240.REF.8" rid="LM240.REF.8">8</a>]</p><p>In a telephone follow-up study, 124 mothers who took a benzodiazepine while nursing reported whether their infants had any signs of sedation. One mother who was taking 0.75 mg of risperidone daily, flurazepam 15 mg daily, clonazepam 0.25 mg twice daily, and 1 mg of bupropion daily reported sedation in her breastfed infant.[<a class="bibr" href="#LM240.REF.11" rid="LM240.REF.11">11</a>]</p><p>A woman diagnosed with schizophrenia was taking risperidone 1.5 mg daily during late pregnancy and postpartum while nursing (extent not stated) her full-term infant. At 2 weeks postpartum, haloperidol 0.8 mg daily was added because of a recurrence of symptoms. At these dosages, no adverse effects were seen in the infant. However, because of recurring symptoms, the dosage of haloperidol was increased to 1.5 mg daily. Three days later, the infant had excessive sedation, poor feeding, and slowing in motor movements. Pediatric assessment found no medical reason for these effects. Breastfeeding was discontinued and the infant's symptoms resolved completely in 5 days. The infant's symptoms were probably caused by the drug combination.[<a class="bibr" href="#LM240.REF.12" rid="LM240.REF.12">12</a>]</p><p>A prospective cohort study of infants breastfed by mothers in an inpatient mother-baby psychiatric unit in India followed 7 infants who were exposed to risperidone in breastmilk; most received partial supplementation. One infant whose mother was taking risperidone 4 mg and lorazepam 2 mg developed sedation that resolved when lorazepam was discontinued. One infant whose mother received risperidone 4 mg daily, trihexyphenidyl 2 mg daily, and electroconvulsive therapy developed constipation. Infants were followed for 1 to 3 months after discharge. One infant had delayed weight development, one infant had delay in height, one infant mental delay, and a fourth infant had motor and mental delay.[<a class="bibr" href="#LM240.REF.13" rid="LM240.REF.13">13</a>]</p><p>A woman with bipolar disorder was maintained on oral risperidone 2 mg at bedtime, long-acting injectable risperidone 50 mg intramuscular every 2 weeks, oral citalopram 20 mg daily, and oral benztropine 0.5 mg daily. She became pregnant and maintained the same regimen. Her infant was born at 35 weeks gestational age and was breastfed (extent and duration not stated). At 16 months of age, the infant was doing well and met his developmental milestones.[<a class="bibr" href="#LM240.REF.14" rid="LM240.REF.14">14</a>]</p><p>Patients enlisted in the National Pregnancy Registry for Atypical Antipsychotics who were taking a second-generation antipsychotic drug while breastfeeding (n = 576) were compared to control breastfeeding patients who were not treated with a second-generation antipsychotic (n = 818). Of the patients who were taking a second-generation antipsychotic drug, 60.4% were on more than one psychotropic. A review of the pediatric medical records, no adverse effects were noted among infants exposed or not exposed to second-generation antipsychotic monotherapy or to polytherapy.[<a class="bibr" href="#LM240.REF.15" rid="LM240.REF.15">15</a>] The number of women taking risperidone was not reported.</p><p>A preterm infant weighing 2.75 kg was born at 35 weeks gestation. The infant received bag and mask ventilation for 2 min and was kept on oxygen for the first 18 hours of life due to respiratory distress. The baby began breastfeeding on day 2 of life. On day 12, the mother was started on risperidone 1 mg daily for psychotic episodes. On day 13, the infant developed a respiratory rate of 16/min and no retractions and was placed on CPAP for 12 hours, with gradual weaning thereafter and was placed on formula. On day 15, the mother began breastfeeding again and the respiratory depression recurred. Feeding was changed to breastmilk expressed prior to the daily dose of risperidone and formula for 6 hours after each dose followed by direct breastfeeding. Over the next 2 days no further episodes of respiratory depression occurred. The baby was discharged on day 24, with advice to continue the same feeding pattern. Respiratory depression was probably caused by risperidone in milk.[<a class="bibr" href="#LM240.REF.16" rid="LM240.REF.16">16</a>]</p><p>A woman diagnosed with undifferentiated schizophrenia took risperidone 4 to 5 mg and trihexyphenidyl 2 mg daily throughout 5 pregnancies. She breastfed each infant for 20 to 24 months. No adverse developmental consequences were noted in any of the children. At the time of publication, the oldest three children, aged 26, 23 and 22 years, had completed their education and were employed, while the youngest two were 15 and 19 years old and were doing well academically in their education.[<a class="bibr" href="#LM240.REF.17" rid="LM240.REF.17">17</a>]</p></div><div id="LM240.Effects_on_Lactation_and_Breastmil"><h3>Effects on Lactation and Breastmilk</h3><p>Risperidone has caused elevated prolactin serum levels, gynecomastia, and galactorrhea in patients taking the drug.[<a class="bibr" href="#LM240.REF.18" rid="LM240.REF.18">18</a>-<a class="bibr" href="#LM240.REF.33" rid="LM240.REF.33">33</a>] In one case, euprolactinemic gynecomastia and galactorrhea occurred in a 19-year-old man who was also taking fluvoxamine.[<a class="bibr" href="#LM240.REF.34" rid="LM240.REF.34">34</a>] A meta-analysis of 3 studies found that the risk of gynecomastia with risperidone is 4.3 times greater than that of quetiapine.[<a class="bibr" href="#LM240.REF.35" rid="LM240.REF.35">35</a>] The prolactin level in a mother with established lactation may not affect her ability to breastfeed.</p><p>Patients enlisted in the National Pregnancy Registry for Atypical Antipsychotics who were taking a second-generation antipsychotic drug while breastfeeding (n = 576) were compared to control breastfeeding patients who primarily had diagnoses of major depressive disorder and anxiety disorders, most often treated with SSRI or SNRI antidepressants, but not with a second-generation antipsychotic (n = 818). Among women on a second-generation antipsychotic, 60.4% were on more than one psychotropic compared with 24.4% among women in the control group. Of the women on a second-generation antipsychotic, 59.3% reported “ever breastfeeding” compared to 88.2% of women in the control group. At 3 months postpartum, 23% of women on a second-generation antipsychotic were exclusively breastfeeding compared to 47% of women in the control group.[<a class="bibr" href="#LM240.REF.15" rid="LM240.REF.15">15</a>] The number of women taking risperidone was not reported.</p></div><div id="LM240.Alternate_Drugs_to_Consider"><h3>Alternate Drugs to Consider</h3><p>(Antipsychotic) <a href="/books/n/lactmed/LM132/?report=reader">Haloperidol</a>, <a href="/books/n/lactmed/LM205/?report=reader">Olanzapine</a>, <a href="/books/n/lactmed/LM233/?report=reader">Quetiapine</a>, <a href="/books/NBK501095/?report=reader">Risperidone</a> (Bipolar Disorder) <a href="/books/n/lactmed/LM437/?report=reader">Divalproex</a>, <a href="/books/n/lactmed/LM293/?report=reader">Lithium</a>, <a href="/books/n/lactmed/LM205/?report=reader">Olanzapine</a>, <a href="/books/n/lactmed/LM233/?report=reader">Quetiapine</a>, <a href="/books/n/lactmed/LM403/?report=reader">Valproic Acid</a></p></div><div id="LM240.References"><h3>References</h3><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="LM240.REF.1">Uguz
|
|
F.
|
|
Second-generation antipsychotics during the lactation period: A comparative systematic review on infant safety.
|
|
J Clin Psychopharmacol
|
|
2016;36:244-52.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/27028982" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27028982</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="LM240.REF.2">Pacchiarotti
|
|
I, Leon-Caballero
|
|
J, Murru
|
|
A, et al.
|
|
Mood stabilizers and antipsychotics during breastfeeding: Focus on bipolar disorder.
|
|
Eur Neuropsychopharmacol
|
|
2016;26:1562-78.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/27568278" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27568278</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><div class="bk_ref" id="LM240.REF.3">Larsen
|
|
ER, Damkier
|
|
P, Pedersen
|
|
LH, et al.
|
|
Use of psychotropic drugs during pregnancy and breast-feeding.
|
|
Acta Psychiatr Scand Suppl
|
|
2015;445:1-28.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/26344706" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26344706</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd><div class="bk_ref" id="LM240.REF.4">Uguz
|
|
F.
|
|
A new safety scoring system for the use of psychotropic drugs during lactation.
|
|
Am J Ther
|
|
2021;28:e118-e26.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/30601177" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30601177</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>5.</dt><dd><div class="bk_ref" id="LM240.REF.5">Hill
|
|
RC, McIvor
|
|
RJ, Wojnar-Horton
|
|
RE, et al.
|
|
Risperidone distribution and excretion into human milk: Case report and estimated infant exposure during breast-feeding.
|
|
J Clin Psychopharmacol
|
|
2000;20:285-6.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/10770482" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10770482</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>6.</dt><dd><div class="bk_ref" id="LM240.REF.6">Ilett
|
|
KF, Hackett
|
|
LP, Kristensen
|
|
JH, et al.
|
|
Transfer of risperidone and 9-hydroxyrisperidone into human milk.
|
|
Ann Pharmacother
|
|
2004;38:273-6.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/14742766" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14742766</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>7.</dt><dd><div class="bk_ref" id="LM240.REF.7">Aichhorn
|
|
W, Stuppaeck
|
|
C, Whitworth
|
|
AB. Risperidone and breast-feeding.
|
|
J Psychopharmacol
|
|
2005;19:211-3.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/15728443" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15728443</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>8.</dt><dd><div class="bk_ref" id="LM240.REF.8">Weggelaar
|
|
NM, Keijer
|
|
WJ, Janssen
|
|
PK. A case report of risperidone distribution and excretion into human milk: How to give good advice if you have not enough data available.
|
|
J Clin Psychopharmacol
|
|
2011;31:129-31.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/21192160" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21192160</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>9.</dt><dd><div class="bk_ref" id="LM240.REF.9">Konishi
|
|
T, Kitahiro
|
|
Y, Fujiwara
|
|
N, et al.
|
|
Pharmacokinetics of brexpiprazole, quetiapine, risperidone, and its active metabolite paliperidone in a postpartum woman and her baby.
|
|
Ther Drug Monit
|
|
2024;46:687-91.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/38648649" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 38648649</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>10.</dt><dd><div class="bk_ref" id="LM240.REF.10">Ratnayake
|
|
T, Libretto
|
|
SE. No complications with risperidone treatment before and throughout pregnancy and during the nursing period.
|
|
J Clin Psychiatry
|
|
2002;63:76-7.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/11838633" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11838633</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>11.</dt><dd><div class="bk_ref" id="LM240.REF.11">Kelly
|
|
LE, Poon
|
|
S, Madadi
|
|
P, et al.
|
|
Neonatal benzodiazepines exposure during breastfeeding.
|
|
J Pediatr
|
|
2012;161:448-51.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/22504099" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22504099</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>12.</dt><dd><div class="bk_ref" id="LM240.REF.12">Uguz
|
|
F.
|
|
Adverse events in a breastfed infant exposed to risperidone and haloperidol.
|
|
Breastfeed Med
|
|
2019;14:683-4.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/31135176" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31135176</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>13.</dt><dd><div class="bk_ref" id="LM240.REF.13">Sinha
|
|
SK, Thomas Kishore
|
|
M, Thippeswamy
|
|
H, et al.
|
|
Adverse effects and short-term developmental outcomes of infants exposed to atypical antipsychotics during breastfeeding.
|
|
Indian J Psychiatry
|
|
2021;63:52-7.
|
|
[<a href="/pmc/articles/PMC8106424/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8106424</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34083820" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34083820</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>14.</dt><dd><div class="bk_ref" id="LM240.REF.14">Clinebell
|
|
K, Gannon
|
|
J, Debrunner
|
|
S, et al.
|
|
Long-acting risperidone injections in a pregnant patient with bipolar disorder.
|
|
Bipolar Disord
|
|
2017;19:606-7.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/29120507" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29120507</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>15.</dt><dd><div class="bk_ref" id="LM240.REF.15">Viguera
|
|
AC, Vanderkruik
|
|
R, Gaccione
|
|
P, et al.
|
|
Breastfeeding practices among women taking second-generation antipsychotics: findings from the National Pregnancy Registry for Atypical Antipsychotics.
|
|
Arch Womens Ment Health
|
|
2022;25:511-6.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/34318375" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34318375</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>16.</dt><dd><div class="bk_ref" id="LM240.REF.16">Pasi
|
|
R, Appikatla
|
|
MB, Babu
|
|
TA. Risperidone-induced respiratory depression in a neonate through breast milk.
|
|
Indian J Pharmacol
|
|
2023;55:185-6.
|
|
[<a href="/pmc/articles/PMC10501541/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC10501541</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37555414" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37555414</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>17.</dt><dd><div class="bk_ref" id="LM240.REF.17">Mendhekar D, Andrade C. A 26-year follow-up of a woman with 5 consecutive children exposed to risperidone during pregnancy and breastfeeding. Prim Care Companion CNS Disord 2024;26:23cr03660. [<a href="https://pubmed.ncbi.nlm.nih.gov/38300980" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 38300980</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>18.</dt><dd><div class="bk_ref" id="LM240.REF.18">Schreiber
|
|
S, Segman
|
|
RH. Risperidone-induced galactorrhea.
|
|
Psychopharmacology (Berl)
|
|
1997;130:300-1.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/9151366" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9151366</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>19.</dt><dd><div class="bk_ref" id="LM240.REF.19">Popli
|
|
A, Gupta
|
|
S, Rangwani
|
|
SR. Risperidone-induced galactorrhea associated with prolactin elevation.
|
|
Ann Clin Psychiatry
|
|
1998;10:31-3.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/9622047" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9622047</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>20.</dt><dd><div class="bk_ref" id="LM240.REF.20">Benazzi
|
|
F.
|
|
Gynecomastia with risperidone-fluoxetine combination.
|
|
Pharmacopsychiatry
|
|
1999;32:41.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/10071182" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10071182</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>21.</dt><dd><div class="bk_ref" id="LM240.REF.21">Gupta
|
|
S, Frank
|
|
B, Madhusoodanan
|
|
S. Risperidone-associated galactorrhea in a male teenager.
|
|
J Am Acad Child Adolesc Psychiatry
|
|
2001;40:504-5.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/11349691" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11349691</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>22.</dt><dd><div class="bk_ref" id="LM240.REF.22">Holzer
|
|
L, Eap
|
|
CB. Risperidone-induced symptomatic hyperprolactinaemia in adolescents.
|
|
J Clin Psychopharmacol
|
|
2006;26:167-71.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/16633146" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16633146</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>23.</dt><dd><div class="bk_ref" id="LM240.REF.23">Madhusoodanan
|
|
S, Moise
|
|
D. Risperidone-induced hyperprolactinemia in adolescents: A case series.
|
|
J Clin Psychiatry
|
|
2006;67:1110-3.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/16889455" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16889455</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>24.</dt><dd><div class="bk_ref" id="LM240.REF.24">Afzal
|
|
KI, Briones
|
|
DF, DeVargas
|
|
C. Risperidone-induced polydipsia and polyphagia associated with galactorrhea, abdominal pain, and rapid weight gain in an adolescent Hispanic female.
|
|
CNS Spectr
|
|
2007;12:818-20.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/17984854" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17984854</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>25.</dt><dd><div class="bk_ref" id="LM240.REF.25">Sakaguchi
|
|
S, Aizawa
|
|
K. Galactorrhea induced by risperidone.
|
|
Intern Med
|
|
2019;58:3609-10.
|
|
[<a href="/pmc/articles/PMC6949440/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6949440</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31366801" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31366801</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>26.</dt><dd><div class="bk_ref" id="LM240.REF.26">Agapoff
|
|
JR
|
|
4th, Olson
|
|
DJ, White
|
|
S, et al.
|
|
Rapid and sustained resolution of risperidone associated hyperprolactinemia and galactorrhea with low-dose lurasidone.
|
|
J Clin Psychopharmacol
|
|
2020;40:410-2.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/32555004" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32555004</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>27.</dt><dd><div class="bk_ref" id="LM240.REF.27">Glocker
|
|
C, Grohmann
|
|
R, Engel
|
|
R, et al.
|
|
Galactorrhea during antipsychotic treatment: Results from AMSP, a drug surveillance program, between 1993 and 2015.
|
|
Eur Arch Psychiatry Clin Neurosci
|
|
2021;271:1425-35.
|
|
[<a href="/pmc/articles/PMC8563638/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8563638</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33768297" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33768297</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>28.</dt><dd><div class="bk_ref" id="LM240.REF.28">Bray
|
|
B, Karri
|
|
M. Risperidone induced hyperprolactinemia levels-never seen before.
|
|
Endocr Pract
|
|
2022;28:S105. doi:10.1016/j.eprac.2022.03.251 [<a href="http://dx.crossref.org/10.1016/j.eprac.2022.03.251" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">CrossRef</a>]</div></dd></dl><dl class="bkr_refwrap"><dt>29.</dt><dd><div class="bk_ref" id="LM240.REF.29">Stojkovic
|
|
M, Radmanovic
|
|
B, Jovanovic
|
|
M, et al.
|
|
Risperidone induced hyperprolactinemia: From basic to clinical studies.
|
|
Front Psychiatry
|
|
2022;13:874705.
|
|
[<a href="/pmc/articles/PMC9121093/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9121093</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35599770" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35599770</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>30.</dt><dd><div class="bk_ref" id="LM240.REF.30">Ranjbar
|
|
F, Sadeghi-Bazargani
|
|
H, Niari Khams
|
|
P, et al.
|
|
Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia.
|
|
Neuropsychiatr Dis Treat
|
|
2015;11:549-55.
|
|
[<a href="/pmc/articles/PMC4356449/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4356449</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25784810" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25784810</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>31.</dt><dd><div class="bk_ref" id="LM240.REF.31">Lee
|
|
BH, Kim
|
|
YK, Park
|
|
SH. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: A pilot study.
|
|
Prog Neuropsychopharmacol Biol Psychiatry
|
|
2006;30:714-7.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/16571367" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16571367</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>32.</dt><dd><div class="bk_ref" id="LM240.REF.32">Lu
|
|
ML, Shen
|
|
WW, Chen
|
|
CH. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
|
|
Prog Neuropsychopharmacol Biol Psychiatry
|
|
2008;32:1978-81.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/18848860" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18848860</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>33.</dt><dd><div class="bk_ref" id="LM240.REF.33">Kelly
|
|
DL, Conley
|
|
RR. A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia.
|
|
Psychoneuroendocrinology
|
|
2006;31:340-6.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/16198059" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16198059</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>34.</dt><dd><div class="bk_ref" id="LM240.REF.34">Pratheesh
|
|
PJ, Praharaj
|
|
SK, Srivastava
|
|
A. Euprolactinemic gynecomastia and galactorrhea with risperidone-fluvoxamine combination.
|
|
Psychopharmacol Bull
|
|
2011;44:70-3.
|
|
[<a href="/pmc/articles/PMC5044559/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5044559</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22506441" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22506441</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>35.</dt><dd><div class="bk_ref" id="LM240.REF.35">Trinchieri
|
|
A, Perletti
|
|
G, Magri
|
|
V, et al.
|
|
Drug-induced gynecomastia: A systematic review and meta-analysis of randomized clinical trials.
|
|
Arch Ital Urol Androl
|
|
2021;93:489-96.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/34933535" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34933535</span></a>]</div></dd></dl></dl></div></div><div id="LM240.Substance_Identification"><h2 id="_LM240_Substance_Identification_">Substance Identification</h2><div id="LM240.Substance_Name"><h3>Substance Name</h3><p>Risperidone</p></div><div id="LM240.CAS_Registry_Number"><h3>CAS Registry Number</h3><p>106266-06-2</p></div><div id="LM240.Drug_Class"><h3>Drug Class</h3><p>Breast Feeding</p><p>Lactation</p><p>Milk, Human</p><p>Antipsychotic Agents</p></div></div><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_top_margin"><p><b>Disclaimer: </b>Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.</p></p></div></dd></dl></dl></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK501095_pubdet_">Publication Details</h2><h3>Publication History</h3><p class="small">Last Revision: <span itemprop="dateModified">January 15, 2025</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a><p class="small"><b>Attribution Statement:</b> LactMed is a registered trademark of the U.S. Department of Health and Human Services.</p></div></div><h3>Publisher</h3><p><a href="https://www.nlm.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Institute of Child Health and Human Development</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Risperidone. [Updated 2025 Jan 15].<span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/lactmed/LM721/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/lactmed/ritlecitinib/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal104 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|